LT3290404T - 5-((halogenfenil)-3-halogen-piridin-2-il)-nitrilo dariniai, kaip tarpininkai [(5-(halogenfenil)-3-hidroksipiridino-2-karbonil)-amino]alkano rūgšties darinių paruošimo būde - Google Patents

5-((halogenfenil)-3-halogen-piridin-2-il)-nitrilo dariniai, kaip tarpininkai [(5-(halogenfenil)-3-hidroksipiridino-2-karbonil)-amino]alkano rūgšties darinių paruošimo būde

Info

Publication number
LT3290404T
LT3290404T LTEP17191362.7T LT17191362T LT3290404T LT 3290404 T LT3290404 T LT 3290404T LT 17191362 T LT17191362 T LT 17191362T LT 3290404 T LT3290404 T LT 3290404T
Authority
LT
Lithuania
Prior art keywords
halogenphenyl
nitryl
halogeno
pyridin
intermediates
Prior art date
Application number
LTEP17191362.7T
Other languages
English (en)
Lithuanian (lt)
Inventor
Christopher LANTHIER
Boris Gorin
Jan Oudenes
Craig Dixon
Alan Lu
James COPP
John JANUSZ
Original Assignee
Akebia Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc. filed Critical Akebia Therapeutics Inc.
Publication of LT3290404T publication Critical patent/LT3290404T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
LTEP17191362.7T 2011-06-06 2012-06-05 5-((halogenfenil)-3-halogen-piridin-2-il)-nitrilo dariniai, kaip tarpininkai [(5-(halogenfenil)-3-hidroksipiridino-2-karbonil)-amino]alkano rūgšties darinių paruošimo būde LT3290404T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161493536P 2011-06-06 2011-06-06

Publications (1)

Publication Number Publication Date
LT3290404T true LT3290404T (lt) 2020-02-25

Family

ID=47262177

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP17191362.7T LT3290404T (lt) 2011-06-06 2012-06-05 5-((halogenfenil)-3-halogen-piridin-2-il)-nitrilo dariniai, kaip tarpininkai [(5-(halogenfenil)-3-hidroksipiridino-2-karbonil)-amino]alkano rūgšties darinių paruošimo būde
LTEP15189822.8T LT3000808T (lt) 2011-06-06 2012-06-05 5-((halogenfenil)-3-hidroksi-piridin-2-il)-karboksirūgšties dariniai, kaip tarpininkai karbonilamino alkano rūgščių, esterių ir amidų paruošimui
LTEP19214405.3T LT3683209T (lt) 2011-06-06 2012-06-05 [(5-(3-chlorfenil)-3-hidroksipiridin-2-karbonil)-amino]acto rūgšties gavimo būdas iš 5-((3-chlorfenil)-3-chlor-piridin-2-il)-nitrilo ir 5-((halogenfenil)-3-halogen-piridin-2-il)-nitrilo darinių gavimo būdas

Family Applications After (2)

Application Number Title Priority Date Filing Date
LTEP15189822.8T LT3000808T (lt) 2011-06-06 2012-06-05 5-((halogenfenil)-3-hidroksi-piridin-2-il)-karboksirūgšties dariniai, kaip tarpininkai karbonilamino alkano rūgščių, esterių ir amidų paruošimui
LTEP19214405.3T LT3683209T (lt) 2011-06-06 2012-06-05 [(5-(3-chlorfenil)-3-hidroksipiridin-2-karbonil)-amino]acto rūgšties gavimo būdas iš 5-((3-chlorfenil)-3-chlor-piridin-2-il)-nitrilo ir 5-((halogenfenil)-3-halogen-piridin-2-il)-nitrilo darinių gavimo būdas

Country Status (23)

Country Link
US (6) US9145366B2 (OSRAM)
EP (5) EP3683209B1 (OSRAM)
JP (6) JP6290781B2 (OSRAM)
KR (5) KR102000485B1 (OSRAM)
CN (1) CN106518759B (OSRAM)
AU (4) AU2012268426B2 (OSRAM)
CA (2) CA2838194C (OSRAM)
CY (4) CY1117177T1 (OSRAM)
DK (4) DK3000808T3 (OSRAM)
ES (4) ES2771232T3 (OSRAM)
HR (4) HRP20211916T1 (OSRAM)
HU (4) HUE026096T2 (OSRAM)
IL (1) IL229775A (OSRAM)
LT (3) LT3290404T (OSRAM)
MX (2) MX347709B (OSRAM)
NO (1) NO2686520T3 (OSRAM)
PL (4) PL3683209T3 (OSRAM)
PT (4) PT3290404T (OSRAM)
RS (3) RS59902B1 (OSRAM)
RU (2) RU2602083C2 (OSRAM)
SI (4) SI3290404T1 (OSRAM)
SM (3) SMT202000061T1 (OSRAM)
WO (1) WO2012170377A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601730A (en) 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
NO2686520T3 (OSRAM) * 2011-06-06 2018-03-17
PL3007695T3 (pl) * 2013-06-13 2024-07-01 Akebia Therapeutics, Inc. Kompozycje i sposoby leczenia niedokrwistości
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
ES2898476T3 (es) 2014-09-02 2022-03-07 Sunshine Lake Pharma Co Ltd Compuesto de quinolona y uso del mismo
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US20180065933A1 (en) * 2015-03-20 2018-03-08 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії
US10703724B2 (en) 2016-12-13 2020-07-07 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof
IL269623B2 (en) * 2017-03-29 2025-05-01 Emerald Health Pharmaceuticals Inc Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
MX2020011845A (es) * 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
EP3887356B1 (en) 2018-11-28 2023-08-02 Sandoz AG Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
US12134600B2 (en) 2019-04-26 2024-11-05 Kaneka Corporation Method for producing a vadadustat intermediate
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN111087343B (zh) * 2019-11-29 2022-02-18 万华化学集团股份有限公司 一种羟基吡啶配体及其制备方法和催化应用
US20230159462A1 (en) * 2019-12-10 2023-05-25 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
WO2021149724A1 (ja) 2020-01-24 2021-07-29 Ａｐｓジャパン株式会社 光触媒ユニット及び該光触媒ユニットを備えたマスク
US20230286918A1 (en) 2020-07-02 2023-09-14 Akebia Therapeutics, Inc. Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
WO2023111990A1 (en) 2021-12-17 2023-06-22 Akebia Therapeutics, Inc. Selective phd1 inhibitor compounds, compositions, and methods of use
WO2024165507A1 (en) 2023-02-06 2024-08-15 Institut National de la Santé et de la Recherche Médicale Use of hif-1α stabilizing agents for the treatment of type i interferonopathies

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) * 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) * 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
TW219933B (OSRAM) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK0650960T3 (da) 1993-11-02 1997-09-01 Hoechst Ag Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
ATE149486T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
JP2000509047A (ja) 1996-04-30 2000-07-18 ヘキスト・アクチエンゲゼルシヤフト ３―アルコキシピリジン―２―カルボキサミドエステル類、その製法および薬剤としてのその使用
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
HUP0101482A3 (en) 1998-03-23 2002-12-28 Aventis Pharm Prod Inc Piperidinyl and n-amidinopiperidinyl derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
WO2002074981A2 (en) 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP2324834B1 (en) 2001-12-06 2019-05-08 Fibrogen, Inc. Methods of Increasing Endogenous Erythropoietin (EPO)
NZ570777A (en) 2002-05-17 2009-04-30 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
EP1545538A2 (en) * 2002-08-29 2005-06-29 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
MXPA05004033A (es) 2002-10-16 2005-06-08 Isis Innovation Hidroxilasas de asparaginil y moduladores de las mismas.
CA2506799A1 (en) 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
US20080113383A1 (en) 2004-05-28 2008-05-15 Fibro Gen, Inc. Hif Prolyl Hydroxylase Activity Assay
EP1771418A2 (en) 2004-05-31 2007-04-11 Tanabe Seiyaku Co., Ltd. Large conductance calcium-activated k channel opener
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
US20080213404A1 (en) 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
CN101849943A (zh) 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
MX2007016160A (es) 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
CA2634168C (en) 2005-12-09 2013-04-23 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
EP1971618A2 (en) 2006-01-09 2008-09-24 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
EP1983823A1 (en) 2006-01-17 2008-10-29 VIB vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
PE20071020A1 (es) 2006-03-07 2007-12-11 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
JP2009537558A (ja) 2006-05-16 2009-10-29 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害剤
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
NZ601730A (en) 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
CL2008000065A1 (es) 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
US20100056563A1 (en) 2007-04-18 2010-03-04 Deodialsingh Guiadeen Novel 1.8-naphthyridine compounds
CA2683738C (en) 2007-04-18 2012-03-20 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
CA2685216C (en) 2007-05-04 2014-07-08 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
EP2160187B1 (en) 2007-05-16 2013-05-22 Merck Sharp & Dohme Corp. Spiroindalones
RU2009146851A (ru) 2007-05-18 2011-06-27 Байер Шеринг Фарма Акциенгезельшафт (DE) Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
US8268794B2 (en) 2007-08-06 2012-09-18 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
EP2188295A4 (en) 2007-08-10 2011-11-16 Crystalgenomics Inc PYRIDINE DERIVATIVES AND METHODS OF USE
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
AU2008331480A1 (en) 2007-11-30 2009-06-11 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
AU2008329746A1 (en) 2007-11-30 2009-06-04 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
US20100298324A1 (en) 2007-12-19 2010-11-25 Smith Kline Beecham Corporation Prolyl Hydroxylase Inhibitors
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
MY150481A (en) * 2008-03-03 2014-01-30 Irm Llc Compounds and compositions as tlr activity modulators
US20090228298A1 (en) * 2008-03-04 2009-09-10 The General Electric Company System and method of morphology feature analysis of physiological data
RU2010142937A (ru) * 2008-03-20 2012-04-27 Форест Лабораториес Холдингс Лимитед (Bm) НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
ES2383273T3 (es) * 2008-07-23 2012-06-19 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos
CN102149703B (zh) 2008-09-15 2014-09-10 卡斯娜莱拉伊诺制药私人有限公司 抗癌药物及将其用于治疗转移性恶性黑色素瘤及其他癌症
US8927591B2 (en) 2008-11-14 2015-01-06 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
WO2010113942A1 (ja) * 2009-03-31 2010-10-07 キッセイ薬品工業株式会社 インドリジン誘導体及びその医薬用途
NZ600400A (en) 2009-11-06 2014-09-26 Aerpio Therapeutics Inc Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
NO2686520T3 (OSRAM) * 2011-06-06 2018-03-17
CN103717214A (zh) 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
CN104024227B8 (zh) 2011-07-22 2025-07-29 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
PL3007695T3 (pl) 2013-06-13 2024-07-01 Akebia Therapeutics, Inc. Kompozycje i sposoby leczenia niedokrwistości
AU2014306496A1 (en) 2013-08-16 2016-03-03 Ohio State Innovation Foundation Compositions and methods for modulating DNA methylation
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
CN106132201A (zh) 2014-01-23 2016-11-16 阿克比治疗有限公司 用于治疗眼部疾病的组合物和方法
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US20180065933A1 (en) 2015-03-20 2018-03-08 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії
MX2020011845A (es) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.

Also Published As

Publication number Publication date
ES2559850T3 (es) 2016-02-16
NO2686520T3 (OSRAM) 2018-03-17
KR20190031593A (ko) 2019-03-26
HK1252109A1 (en) 2019-05-17
JP6510094B2 (ja) 2019-05-08
IL229775A (en) 2016-06-30
KR20190141805A (ko) 2019-12-24
MX347709B (es) 2017-05-10
JP2014522409A (ja) 2014-09-04
CY1117177T1 (el) 2017-04-05
SMT201600013B (it) 2016-02-25
PL3290404T3 (pl) 2020-06-01
CY1122639T1 (el) 2021-03-12
HK1216173A1 (en) 2016-10-21
HUE034975T2 (en) 2018-05-02
ES2647602T3 (es) 2017-12-22
JP7685552B2 (ja) 2025-05-29
US20120309977A1 (en) 2012-12-06
US20170362178A1 (en) 2017-12-21
JP2021059573A (ja) 2021-04-15
EP3000808A1 (en) 2016-03-30
HUE048044T2 (hu) 2020-05-28
AU2012268426B2 (en) 2017-02-16
CN103717575A (zh) 2014-04-09
EP2718265A4 (en) 2014-11-19
NZ618570A (en) 2015-07-31
WO2012170377A1 (en) 2012-12-13
PL3683209T3 (pl) 2022-02-21
EP4026829A1 (en) 2022-07-13
CA2838194C (en) 2022-01-11
US20210122715A1 (en) 2021-04-29
AU2018250355A1 (en) 2018-11-08
EP3683209B1 (en) 2021-11-10
EP2718265B1 (en) 2015-12-16
DK3000808T3 (da) 2017-11-27
SI3683209T1 (sl) 2022-03-31
JP2022081597A (ja) 2022-05-31
SMT202000061T1 (it) 2020-03-13
JP6816195B2 (ja) 2021-01-20
HRP20200197T1 (hr) 2020-05-15
CY1119605T1 (el) 2018-04-04
RU2602083C2 (ru) 2016-11-10
EP3000808B1 (en) 2017-09-27
RU2016139352A3 (OSRAM) 2020-01-27
DK3683209T3 (da) 2021-12-06
LT3000808T (lt) 2018-01-25
HUE057571T2 (hu) 2022-05-28
DK2718265T3 (en) 2016-01-25
KR20200121911A (ko) 2020-10-26
MX337216B (es) 2016-02-18
RS54517B1 (sr) 2016-06-30
KR20190032617A (ko) 2019-03-27
CN106518759B (zh) 2019-07-30
KR102000485B1 (ko) 2019-07-16
HK1196616A1 (zh) 2014-12-19
RS56580B1 (sr) 2018-02-28
RU2764667C2 (ru) 2022-01-19
KR102059366B1 (ko) 2019-12-26
ES2771232T3 (es) 2020-07-06
PT3290404T (pt) 2020-02-19
PL3000808T3 (pl) 2018-03-30
CN106518759A (zh) 2017-03-22
PT2718265E (pt) 2016-02-15
RU2016139352A (ru) 2018-12-13
HUE026096T2 (en) 2016-05-30
US20190375713A1 (en) 2019-12-12
EP3290404A1 (en) 2018-03-07
JP2019123741A (ja) 2019-07-25
PT3683209T (pt) 2021-12-15
LT3683209T (lt) 2022-01-10
EP3290404B1 (en) 2019-12-11
US9776969B2 (en) 2017-10-03
AU2020204528A1 (en) 2020-07-30
CY1124874T1 (el) 2022-11-25
KR20140037192A (ko) 2014-03-26
AU2018250355B2 (en) 2020-04-09
JP7039682B2 (ja) 2022-03-22
EP2718265A1 (en) 2014-04-16
AU2012268426A1 (en) 2014-01-09
JP2018111697A (ja) 2018-07-19
SMT201700534T1 (it) 2018-01-11
RU2013158640A (ru) 2015-07-20
US11267785B2 (en) 2022-03-08
SI2718265T1 (sl) 2016-03-31
SI3000808T1 (en) 2018-02-28
EP3683209A1 (en) 2020-07-22
HRP20211916T1 (hr) 2022-03-18
AU2017202414A1 (en) 2017-05-04
JP2023103414A (ja) 2023-07-26
AU2017202414B2 (en) 2018-07-19
KR102032864B1 (ko) 2019-10-16
PT3000808T (pt) 2017-11-23
KR102171315B1 (ko) 2020-10-28
CA2838194A1 (en) 2012-12-13
US20150361043A1 (en) 2015-12-17
PL2718265T3 (pl) 2016-04-29
RS59902B1 (sr) 2020-03-31
US10738010B2 (en) 2020-08-11
ES2900572T3 (es) 2022-03-17
SI3290404T1 (sl) 2020-03-31
DK3290404T3 (da) 2020-02-17
HRP20151416T1 (hr) 2016-03-25
US9145366B2 (en) 2015-09-29
AU2020204528B2 (en) 2022-07-14
US10246416B2 (en) 2019-04-02
JP7284309B2 (ja) 2023-05-30
MX2013014228A (es) 2014-03-26
CA3135440A1 (en) 2012-12-13
HRP20171740T1 (hr) 2018-03-09
US20230002323A1 (en) 2023-01-05
KR102293016B1 (ko) 2021-08-26
JP6290781B2 (ja) 2018-03-07

Similar Documents

Publication Publication Date Title
LT3290404T (lt) 5-((halogenfenil)-3-halogen-piridin-2-il)-nitrilo dariniai, kaip tarpininkai [(5-(halogenfenil)-3-hidroksipiridino-2-karbonil)-amino]alkano rūgšties darinių paruošimo būde
HUS1700040I1 (hu) Antivirális 1-fenil-2,5-dibenzimidazol-5-il-pirrolidin-származék
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
EP2762476A4 (en) 1,2,4-triazine-6-carboxamide derivative
EP2684880A4 (en) DISPIROPYRROLIDINDERIVAT
EP2616024A4 (en) BALANCED PHAKOEMULSIFICATION TIP
CO6910204A2 (es) Derivados de 5-flúor-4-imino-3-(sustituido)-3,4-dihidropirimidin-2(1h)ona
LT2694484T (lt) Pirimidino dariniai, skirti virusinių infekcijų gydymui
BR112013019509A2 (pt) derivados heterocíclicos
DK2661243T3 (da) Konstruktioner, opnåede ved vævsteknologi
BR112013024378A2 (pt) novos derivados de pirimidina
EP2735712A4 (en) CONSTRUCTION MACHINE
DK2734499T3 (da) Merocyanine derivatives
BR112014010169A2 (pt) derivado n-tienilbenzamida substituída com aminoalquil
IL231950B (en) Aryl-quinoline derivatives
BR112013023056A2 (pt) derivados de oxaespiro [2,5] octano e análogos
EP2672151A4 (en) COMBINED PISTON RING
PT2798205E (pt) Turbomáquina
CO6811866A2 (es) Derivados de benzamida sustituida
DK3070091T3 (da) Benzodioxolderivater som phosphodiesterasehæmmere
EP2679827A4 (en) TURBO DEVICE
CO6960557A2 (es) Derivados de 2-yodo-imidazol
CO6920301A2 (es) Derivados insecticidas de 2-metoxibenzamida
IL230609A0 (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
BR112013023539A2 (pt) derivados de isoxazolidina